We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

67 hedge funds and large institutions have $109M invested in Ovid Therapeutics in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 22 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.51% more ownership

Funds ownership: 49.45% → 49.96% (+0.51%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less capital invested

Capital invested by funds: $113M → $109M (-$3.68M)

7% less funds holding

Funds holding: 72 → 67 (-5)

31% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 16

32% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 22

Holders
67
Holders Change
-5
Holders Change %
-6.94%
% of All Funds
1.03%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
15
Reduced
22
Closed
16
Calls
$1.2M
Puts
–
Net Calls
+$1.2M
Net Calls Change
+$2.11M

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$2.58M
2
Russell Investments Group
Russell Investments Group
United Kingdom
+$1.05M
3
CA
CHI Advisors
New York
+$570K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$469K
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$461K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$1.37M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$1.12M
3
E
Ergoteles
New York
-$560K
4
HF
HRT Financial
New York
-$384K
5
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
-$274K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$21.3M – – –
EC
2
EcoR1 Capital
California
$19.5M – – –
SCM
3
Stonepine Capital Management
Oregon
$12.9M +$2.58M +753,293 +23%
Vanguard Group
4
Vanguard Group
Pennsylvania
$11.1M +$207K +60,537 +2%
AG
5
Artal Group
Luxembourg
$8.03M – – –
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$6.54M +$469K +136,922 +7%
GC
7
Globeflex Capital
California
$4.49M -$1.21K -353 -0%
BlackRock
8
BlackRock
New York
$3.68M -$17.7K -5,161 -0.4%
PIM
9
Platinum Investment Management
Australia
$2.46M – – –
D.E. Shaw & Co
10
D.E. Shaw & Co
New York
$2.44M +$103K +30,166 +4%
IC
11
Ikarian Capital
Texas
$2.26M -$1.37M -400,000 -36%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.84M +$78.7K +22,959 +4%
Wells Fargo
13
Wells Fargo
California
$1.45M -$6K -1,750 -0.4%
CA
14
CHI Advisors
New York
$1.28M +$570K +166,490 +71%
Millennium Management
15
Millennium Management
New York
$1.24M -$92.9K -27,124 -7%
Russell Investments Group
16
Russell Investments Group
United Kingdom
$983K +$1.05M +306,556 New
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$919K +$305K +89,105 +45%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$810K +$461K +134,673 +115%
BCM
19
Bridgeway Capital Management
Texas
$679K – – –
State Street
20
State Street
Massachusetts
$465K – – –
DA
21
DCF Advisers
Connecticut
$455K – – –
Connor, Clark & Lunn Investment Management (CC&L)
22
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$384K -$274K -80,000 -40%
SEI Investments
23
SEI Investments
Pennsylvania
$383K +$132K +38,657 +48%
William Blair & Company
24
William Blair & Company
Illinois
$292K -$21.1K -6,146 -6%
Northern Trust
25
Northern Trust
Illinois
$280K – – –
1
2 3 4

OVID Hedge Fund Activity: Q4 2021 in Review

67 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q4 2021, worth a combined $109M — down 3.3% from $113M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of OVID and 11 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 15 added.

The largest buyer was Stonepine Capital Management, adding an estimated $2.58M. The largest seller was Ikarian Capital, cutting an estimated $1.37M.

  • 67 institutional investors held Ovid Therapeutics (OVID) as of Q4 2021, down from 72 in Q3 2021.
  • Funds reported $109M of Ovid Therapeutics stock for Q4 2021, down 3.3% quarter-over-quarter.
  • 11 funds opened new Ovid Therapeutics positions in Q4 2021 and 16 closed out, a net change of -5 holders.
  • The largest Ovid Therapeutics buyer in Q4 2021 was Stonepine Capital Management, an estimated $2.58M added.
  • The largest Ovid Therapeutics seller in Q4 2021 was Ikarian Capital, an estimated $1.37M sold.

Based on aggregated 13F filings for Q4 2021.